articleTop 1% cited
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
The Lancet Oncology · 2014 · Vol. 15(10) · pp. 1065–1075
Volker Heinemann✉Ludwig Fischer von Weikersthal(Klinikum St. Marien Amberg)Thomas DeckerAlexander Kiani(Bayreuth Medical Center)Ursula Vehling‐Kaiser(University of Applied Sciences Landshut)Salah‐Eddin Al‐Batran(Krankenhaus Nordwest)Tobias Heintges(Lukaskrankenhaus)Christian LerchenmüllerChristoph Kahl(Klinikum Magdeburg)G. SeipeltFrank Kullmann(Klinikum Weiden)Martina StauchWerner Scheithauer(Comprehensive Cancer Center Vienna)Jörg Hielscher(Klinikum Chemnitz)Michael Scholz(Klinikum Stuttgart)Sebastian MüllerHartmut Link(Westpfalz Klinikum)N. Niederle(Klinikum Leverkusen)A. Rost(Klinikum Darmstadt)Heinz‐Gert Höffkes(Klinikum Fulda)Markus Moehler(Johannes Gutenberg University Mainz)Reinhard Udo Lindig(Jena University Hospital)Dominik Paul ModestLisa Rossius(Ludwig-Maximilians-Universität München)Thomas Kirchner(Ludwig-Maximilians-Universität München)Andreas Jung(Ludwig-Maximilians-Universität München)Sebastian Stintzing
Colorectal Cancer Treatments and StudiesHepatocellular Carcinoma Treatment and PrognosisGastric Cancer Management and OutcomesFOLFIRIMedicineBevacizumabCetuximabIrinotecanInternal medicineColorectal cancerKRASFolinic acidOncology
MeSH terms
BevacizumabCetuximabAdolescentAdultAgedAntineoplastic Combined Chemotherapy ProtocolsAustriaCamptothecinLeucovorinDose-Response Relationship, DrugDrug Administration ScheduleFemaleFluorouracilGermanyHumans
Funding
- Merck KGaA
Citations
1,720
FWCI
91.27
field-weighted impact
References
28
Percentile
100%
vs. same field & year
Citations per year
Cited by
Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
Oncotarget · 2016 · 325 citations
Drug resistance and new therapies in colorectal cancer
World Journal of Gastroenterology · 2018 · 602 citations
Tumor angiogenesis: causes, consequences, challenges and opportunities
Cellular and Molecular Life Sciences · 2019 · 1,863 citations
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Annals of Oncology · 2016 · 3,389 citations
References
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
Journal of Clinical Oncology · 2007 · 2,267 citations
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor <i>KRAS</i> and <i>BRAF</i> Mutation Status
Journal of Clinical Oncology · 2011 · 1,880 citations
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
The Lancet Oncology · 2010 · 2,133 citations
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
JNCI Journal of the National Cancer Institute · 2000 · 15,689 citations
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
New England Journal of Medicine · 2004 · 10,930 citations
Nonparametric Estimation from Incomplete Observations
Journal of the American Statistical Association · 1958 · 38,793 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.